{"id":"egg-cell-derived-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine contains inactivated influenza virus antigens derived from egg cells, which are used to stimulate the body's immune system to produce antibodies against the influenza virus. These antibodies help to protect against future infections by recognizing and neutralizing the virus.","oneSentence":"Egg cell-derived Influenza Vaccine works by stimulating the body's immune system to produce antibodies against the influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:36:48.261Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention"}]},"trialDetails":[{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT00630331","phase":"PHASE3","title":"Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-10","conditions":"Influenza","enrollment":11404},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05070494","phase":"PHASE4","title":"Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-03-01","conditions":"ESRD, Influenza Vaccine, Seroprotection","enrollment":175},{"nctId":"NCT03314662","phase":"PHASE3","title":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-10-17","conditions":"Influenza, Human","enrollment":1778},{"nctId":"NCT02587221","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-30","conditions":"Influenza","enrollment":6790},{"nctId":"NCT00971906","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":660},{"nctId":"NCT00310804","phase":"PHASE3","title":"Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-09","conditions":"Influenza","enrollment":1200},{"nctId":"NCT00306527","phase":"PHASE3","title":"Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-09","conditions":"Influenza","enrollment":2235},{"nctId":"NCT02600585","phase":"","title":"Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2015-11","conditions":"Human Influenza","enrollment":254648},{"nctId":"NCT01961947","phase":"PHASE3","title":"Study of ASP7374, Cell-culture-derived Influenza Vaccine","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2013-10","conditions":"Influenza, Vaccine","enrollment":900},{"nctId":"NCT01767896","phase":"PHASE3","title":"Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2012-10","conditions":"Influenza","enrollment":1020},{"nctId":"NCT01998477","phase":"PHASE3","title":"A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-10","conditions":"Influenza","enrollment":430},{"nctId":"NCT00264576","phase":"PHASE2","title":"Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-10","conditions":"Influenza Disease; Flu","enrollment":613},{"nctId":"NCT02255279","phase":"PHASE3","title":"Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-10","conditions":"Influenza","enrollment":287},{"nctId":"NCT00579345","phase":"PHASE3","title":"Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Influenza","enrollment":1522},{"nctId":"NCT00972816","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-09","conditions":"Influenza","enrollment":1357},{"nctId":"NCT00560066","phase":"PHASE4","title":"Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"Seasonal Influenza, Vaccine","enrollment":1398},{"nctId":"NCT00492063","phase":"PHASE3","title":"Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-09","conditions":"Influenza","enrollment":2654},{"nctId":"NCT00973349","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-09","conditions":"Influenza","enrollment":2719},{"nctId":"NCT02621177","phase":"PHASE3","title":"Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2013-11","conditions":"Influenza, Human","enrollment":385},{"nctId":"NCT02621164","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-09","conditions":"Influenza, Human","enrollment":454},{"nctId":"NCT00973700","phase":"PHASE3","title":"Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Novel 2009 Influenza H1N1","enrollment":784},{"nctId":"NCT01640327","phase":"PHASE3","title":"Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-07","conditions":"Human, Influenza","enrollment":126},{"nctId":"NCT00645411","phase":"PHASE2, PHASE3","title":"Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Influenza","enrollment":3604},{"nctId":"NCT02427750","phase":"PHASE2","title":"A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.","status":"COMPLETED","sponsor":"Novartis","startDate":"2015-04","conditions":"Human Influenza","enrollment":126},{"nctId":"NCT00424086","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-01","conditions":"Influenza","enrollment":1000},{"nctId":"NCT00289510","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2006-01","conditions":"Influenza","enrollment":423},{"nctId":"NCT00161811","phase":"PHASE2, PHASE3","title":"Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2004-11","conditions":"Influenza","enrollment":1400},{"nctId":"NCT00161837","phase":"PHASE2, PHASE3","title":"Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2003-12","conditions":"Influenza","enrollment":""},{"nctId":"NCT00464672","phase":"PHASE3","title":"Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Influenza","enrollment":1893},{"nctId":"NCT01368796","phase":"PHASE4","title":"Comparison of 4 Influenza Vaccines in Seniors","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-07","conditions":"Influenza Vaccine","enrollment":953},{"nctId":"NCT02344134","phase":"PHASE3","title":"Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2013-09","conditions":"Influenza, Human","enrollment":1155},{"nctId":"NCT01857206","phase":"PHASE3","title":"Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-05","conditions":"Influenza, Fever","enrollment":2055},{"nctId":"NCT01867021","phase":"PHASE4","title":"Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above","status":"COMPLETED","sponsor":"Novartis","startDate":"2013-05","conditions":"Influenza","enrollment":2902},{"nctId":"NCT01879540","phase":"PHASE2","title":"Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-07","conditions":"Human Influenza","enrollment":63},{"nctId":"NCT01885117","phase":"PHASE3","title":"Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-08","conditions":"Human Influenza","enrollment":125},{"nctId":"NCT01879553","phase":"PHASE2","title":"Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-07","conditions":"Human Influenza","enrollment":126},{"nctId":"NCT01209780","phase":"PHASE3","title":"Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"Seasonal Influenza","enrollment":3116},{"nctId":"NCT01079273","phase":"PHASE4","title":"Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Opera CRO, a TIGERMED Group Company","startDate":"2009-12","conditions":"Influenza","enrollment":7},{"nctId":"NCT01013675","phase":"PHASE2","title":"Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly","status":"COMPLETED","sponsor":"Abbott Biologicals","startDate":"2009-11","conditions":"Influenza Vaccines","enrollment":622},{"nctId":"NCT01101074","phase":"","title":"Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-10","conditions":"Influenza A (H1N1)","enrollment":135469},{"nctId":"NCT00971542","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-09","conditions":"Pandemic Influenza","enrollment":778},{"nctId":"NCT01040741","phase":"","title":"Observational Safety Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-12","conditions":"Pandemic Influenza A (H1N1), A New Flu Virus of Swine Origin","enrollment":7284},{"nctId":"NCT00999206","phase":"PHASE3","title":"Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine","status":"COMPLETED","sponsor":"Abbott Biologicals","startDate":"2010-01","conditions":"Influenza","enrollment":3138},{"nctId":"NCT00539864","phase":"PHASE3","title":"Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2007-09","conditions":"Influenza","enrollment":602},{"nctId":"NCT00395174","phase":"PHASE3","title":"Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2006-10","conditions":"Influenza","enrollment":870},{"nctId":"NCT00562237","phase":"PHASE1","title":"Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine","status":"TERMINATED","sponsor":"Solvay Pharmaceuticals","startDate":"2007-07","conditions":"Healthy Subjects","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Egg cell-derived Influenza Vaccine","genericName":"Egg cell-derived Influenza Vaccine","companyName":"Alachua Government Services, Inc.","companyId":"alachua-government-services-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Egg cell-derived Influenza Vaccine works by stimulating the body's immune system to produce antibodies against the influenza virus. Used for Influenza prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}